SCHEMBL24331481

SCHEMBL24331481

CCc1c(Cl)nc(N)nc1-c1c(C)cccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HEXA P06865 5/20 0.41
▸ HEXB P07686 5/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ DHFR P00374 6/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ADORA2A P29274 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ SLC22A1 O15245 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515334 1.00 HEXA (0.41) HEXAHEXBSMN1; SMN2KDM4EHPGD
SCHEMBL24309881 0.84 ADORA2A (0.51) HEXAHEXBSMN1; SMN2KDM4EHPGD
SCHEMBL11154581 0.80 ADORA2A (0.47) HEXAHEXBSMN1; SMN2KDM4EHPGD
SCHEMBL29515320 0.80 HSP90AA1 (0.42) DHFRHSP90AA1ADORA2AKMT2AALDH1A1
SCHEMBL24330396 0.80 HSP90AA1 (0.42) DHFRHSP90AA1ADORA2AKMT2AALDH1A1
SCHEMBL24331365 0.77 HSP90AA1 (0.41) HSP90AA1ADORA2AKMT2AMEN1ADORA1
SCHEMBL29515534 0.77 HSP90AA1 (0.41) HSP90AA1ADORA2AKMT2AADORA1
SCHEMBL24331073 0.77 HSP90AA1 (0.41) HSP90AA1ADORA2AKMT2AADORA1
SCHEMBL29515175 0.74 HSP90AA1 (0.45) HSP90AA1NPSR1ADORA2AADORA1
SCHEMBL24331124 0.74 HSP90AA1 (0.45) HSP90AA1NPSR1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2022076620-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HEXA 1593/4885HEXB 1166/4885SMN1; SMN2 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback